Lumida
/IART
⌘K
Integra Lifesciences Holdings Corp

Integra Lifesciences Holdings Corp

IART
$15.50USD-0.26%-0.04 today

MARKET CAP

1.2B

P/E (TTM)

FWD P/E

DAY RANGE

$15 – $16

52W RANGE

$9
$20

AI Summary

Stalk
Sell NowMedium

IART has broken below its key support zone in a Stage 4 distribution phase, with the primary Support Failure pattern confirming supply dominance. Price trades below the 9EMA, 20EMA, and 50DMA with downward follow-through and no exhaustion signals. The medium-term bias is firmly bearish, and short-term conditions favor selling into any relief rallies toward the short EMAs or the former support area. Long-term uptrend on the 200DMA remains intact but is overshadowed by immediate downside pressure.

  • Compliance Master Plan boosts supply execution and operational stability.
  • Q2 revenue $419M (+7% seq.); adjusted EPS $0.56 tops guidance.
  • Gross margin fell ~350bps, with full-year margins down ~260bps.
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$1.5B$1.6B$1.5B$1.6B$1.6B
YoY %+12.4%+1.0%-1.0%+4.5%+1.5%
P / Sales3.7x3.0x2.3x1.1x0.6x
EV / Sales4.7x4.0x3.5x2.5x2.0x
Gross Profit, Adj.$944.6M$970.3M$884.7M$882.1M$831.6M
YoY %+11.0%+2.7%-8.8%-0.3%-5.7%
Margin %61.2%62.3%57.4%54.8%50.9%
EV / Gross Profit7.7x6.5x6.1x4.5x3.9x
EBITDA, Adj.$317.1M$357.2M$235.0M$169.3M$169.8M
YoY %+18.6%+12.7%-34.2%-28.0%+0.3%
Margin %20.6%22.9%15.2%10.5%10.4%
EV / EBITDA23.1x17.6x22.9x23.6x19.3x
EBIT$197.2M$238.9M$111.5M$28.4M$-493.4M
YoY %+30.3%+21.1%-53.3%-74.5%-1836.5%
Margin %12.8%15.3%7.2%1.8%-30.2%
EV / EBIT37.1x26.3x48.3x140.5x-6.6x
Net Income$169.1M$180.6M$67.7M$-6.9M$-516.5M
YoY %+26.3%+6.8%-62.5%-110.3%-7337.7%
Net Margin11.0%11.6%4.4%-0.4%-31.6%
EPS (GAAP)$1.98$2.16$0.84-$0.09-$6.74
YoY %+26.1%+9.1%-61.1%-110.7%-7388.9%